Abstract
Coronary heart disease (CHD) is the leading cause of death in the United States. CHD risk differs between genders, with coronary events lagging behind ten years for women in comparison to men. Low-density lipoprotein cholesterol lowering with statin therapy is a major target for cardiovascular risk reduction. The benefit of statin therapy has been well established in men, for both primary and secondary prevention. However, the same has not been shown for women. While studies have demonstrated benefit in women for secondary prevention, their role in primary prevention of cardiovascular disease remains controversial. Data released over the past several years regarding statin efficacy and safety in men and women has been inconsistent, given that these studies had small sample sizes with numerous study limitations. A recent large scale meta-analysis of both primary and secondary statin prevention trials with sex-specific outcomes demonstrated a similar benefit in both men and women. Statins demonstrated a decrease in cardiovascular events and all-cause mortality in both sexes. In regards to statin safety, additional trials investigating the difference in adverse events of statins in men versus women, particularly new onset of diabe...Continue Reading
References
Dec 5, 1998·The New England Journal of Medicine·UNKNOWN Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
Jan 20, 1999·Circulation·J F PlehnE Braunwald
Feb 19, 1999·Lancet·D M Lloyd-JonesD Levy
Jan 25, 2000·Clinical Therapeutics·K Nakajima
Nov 28, 2001·Circulation·S YusufS Anand
Feb 19, 2002·Atherosclerosis·Kyoko NishiShinji Nagahiro
Mar 16, 2004·Lancet·Rory CollinsUNKNOWN Heart Protection Study Collaborative Group
Apr 29, 2006·Stroke; a Journal of Cerebral Circulation·Cheryl D BushnellJ Donald Easton
Mar 16, 2007·Current Medical Research and Opinion·Krista M DaleC Michael White
Apr 3, 2007·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·Koichi SakabeYoshiyuki Tamura
Jul 12, 2008·Stroke; a Journal of Cerebral Circulation·Larry B GoldsteinUNKNOWN SPARCL Investigators
Sep 17, 2008·International Journal of Cardiology·Mario PetrettaMassimo Chiariello
Apr 10, 2010·Preventive Cardiology·Radhika N BukkapatnamWilliam R Lewis
Feb 4, 2012·Journal of the American College of Cardiology·William J KostisJohn B Kostis
Jun 27, 2012·Archives of Internal Medicine·Jose GutierrezRalph L Sacco
Jul 26, 2012·Circulation·Kai KappertUNKNOWN ONTARGET/TRANSCEND Investigators
Jan 30, 2014·Annals of Internal Medicine·Neil J StoneUNKNOWN 2013 ACC/AHA Cholesterol Guideline Panel
Mar 22, 2014·The New England Journal of Medicine·Michael J PencinaEric D Peterson
Dec 19, 2014·Circulation·Dariush MozaffarianUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jan 13, 2015·Lancet·UNKNOWN Cholesterol Treatment Trialists' (CTT) CollaborationAnthony Keech
Jan 18, 2015·Lancet·Lori Mosca
Apr 26, 2015·Journal of Clinical Lipidology·Giuliana MombelliCesare R Sirtori
Citations
Feb 13, 2018·Angiology·Matina KouvariDemosthenes B Panagiotakos
Mar 17, 2019·Journal of Clinical Medicine·Catherine J Andersen, Terrence M Vance
Apr 6, 2019·British Journal of Pharmacology·Pedram Honarpisheh, Louise D McCullough
Aug 17, 2019·Experimental Dermatology·Simon M MuellerStefan Borgwardt
Aug 26, 2020·ELife·C M SchoolingG M Leung
Oct 4, 2016·Current Atherosclerosis Reports·Karen M GoldsteinHayden B Bosworth
Nov 3, 2020·European Heart Journal. Cardiovascular Pharmacotherapy·Lluís MasanaOn Behalf Of The Stacov-Xula Research Group
Jul 13, 2019·Current Opinion in Pharmacology·Yasmin SchmidSimon M Mueller
Aug 6, 2021·Molecular Pharmaceutics·Gonçalo S ClementePhilip H Elsinga
Dec 4, 2021·JAMA Network Open·Nikhil SinghParveen K Garg
Dec 5, 2019·Diabetes Spectrum : a Publication of the American Diabetes Association·Jamie M HuffNataliya Scheinberg